Comparing a new biologic (GS101) with Dupixent in healthy volunteers
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests a new biologic medicine (GS101) against an approved treatment (Dupixent) for conditions like atopic dermatitis. It is looking for healthy volunteers to compare how the body processes each drug after an injection under the skin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good general health, with no major medical conditions or chronic diseases.
- Your body mass index (BMI) should be between 19 and 26, and you need to weigh between 55 and 85 kg (about 121 to 187 lbs).
- You cannot have a history of two or more drug or food allergies, or conditions like asthma, hives, or eczema.
- You must test negative for HIV, hepatitis B, hepatitis C, and syphilis.
- You and your partner must agree to use effective birth control from the start of the study until 3 months after the last dose, and you cannot donate sperm or plan a pregnancy during that time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injection called GS101 compared to an existing treatment (Dupixent) for people with moderate-to-severe atopic dermatitis (eczema). If you join, you may receive either the new drug or the standard treatment, and researchers will track how well it controls your symptoms.
This trial tests a new medicine, SSGJ-716, in healthy adults and in people with moderate-to-severe atopic dermatitis (a type of eczema). It aims to see if the drug is safe and how the body reacts to it.
This trial tests a new ointment called CU-10101. It will first be tested in healthy volunteers to check safety, and then in people with atopic dermatitis (eczema) to see how well it works for mild to moderate symptoms.
This trial tests a new version of Dupixent® (called CKD-706) to see how it compares to the approved medicine in healthy adults. It's a first step to make sure the new medicine works similarly and is safe.
This study tests a new version of the medicine Dupixent (called GLR1044) to see if it works the same as the original. It is for healthy men to check safety and how the body handles the medicine.
This study tests whether a new biologic medicine (IBI3027) works as well as an approved medicine (dupilumab) for treating moderate-to-severe eczema. If you join, you may receive one of the two treatments, and researchers will compare their effects on your skin and itching.
Hear when a new Atopic Dermatitis (AD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.